MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Novartis AG

Avatud

132.26 0.79

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

129.91

Max

132.45

Põhinäitajad

By Trading Economics

Sissetulek

418M

4B

Müük

660M

14B

P/E

Sektori keskmine

18.012

35.739

Aktsiakasum

2.42

Dividenditootlus

3.23

Kasumimarginaal

28.18

Töötajad

75,883

EBITDA

-5.8B

4.9M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-13.64% downside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.23%

3.08%

Turustatistika

By TradingEconomics

Turukapital

1.2B

240B

Eelmine avamishind

131.47

Eelmine sulgemishind

132.26

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Novartis AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. okt 2025, 08:54 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

15. sept 2025, 12:07 UTC

Suurimad hinnamuutused turgudel

Monte Rosa Therapeutics Shares Soar on Drug Partnership with Novartis

9. sept 2025, 10:11 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Tourmaline Bio Shares Surge Premarket on Takeover by Novartis

9. sept 2025, 05:52 UTC

Omandamised, ülevõtmised, äriostud

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal

7. aug 2025, 05:47 UTC

Omandamised, ülevõtmised, äriostud

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

17. juuli 2025, 14:26 UTC

Tulu

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17. juuli 2025, 06:49 UTC

Tulu

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17. juuli 2025, 05:41 UTC

Tulu

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

1. okt 2025, 06:47 UTC

Market Talk

Novartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk

29. sept 2025, 11:46 UTC

Omandamised, ülevõtmised, äriostud

Novartis: Offer to Expire Oct. 27

29. sept 2025, 11:45 UTC

Omandamised, ülevõtmised, äriostud

Novartis Has Started Tender Offer to Buy Tourmaline Bio

12. sept 2025, 16:11 UTC

Tulu

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

9. sept 2025, 08:09 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Novartis Makes Strategically Meaningful Move With Tourmaline Deal -- Market Talk

9. sept 2025, 05:04 UTC

Omandamised, ülevõtmised, äriostud

Novartis Offering $48 a Share for Tourmaline

9. sept 2025, 05:04 UTC

Omandamised, ülevõtmised, äriostud

Novartis: Offer Price Values Tourmaline at $1.4B on Fully Diluted Basis

9. sept 2025, 05:03 UTC

Omandamised, ülevõtmised, äriostud

Novartis to Buy Tourmaline Bio in Bid to Complement Cardiovascular Pipeline

9. sept 2025, 05:00 UTC

Omandamised, ülevõtmised, äriostud

Novartis to Buy Tourmaline Bio

11. aug 2025, 11:16 UTC

Tulu

Rheinmetall, Ørsted, Novartis: Global Stocks in Focus -- WSJ

8. aug 2025, 11:26 UTC

Market Talk

Novartis Is Getting Closer to Midterm Targets -- Market Talk

8. aug 2025, 11:07 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Novartis Has Room to Accelerate Dealmaking -- Market Talk

8. aug 2025, 10:51 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

5. aug 2025, 10:40 UTC

Market Talk

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

17. juuli 2025, 11:36 UTC

Market Talk

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17. juuli 2025, 11:26 UTC

Market Talk

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17. juuli 2025, 07:14 UTC

Market Talk

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17. juuli 2025, 07:02 UTC

Market Talk
Tulu

Novartis's Results Look Impressive -- Market Talk

17. juuli 2025, 05:09 UTC

Tulu

Novartis 2Q Sales Grew 11% at Constant Currency

17. juuli 2025, 05:08 UTC

Tulu

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17. juuli 2025, 05:06 UTC

Tulu

Novartis: Mehta's Appointment Is Effective March 2026

17. juuli 2025, 05:05 UTC

Tulu

Novartis: Harry Kirsch Retires After 22 Years With Company

Võrdlus sarnastega

Hinnamuutus

Novartis AG Prognoos

Hinnasiht

By TipRanks

-13.64% langus

12 kuu keskmine prognoos

Keskmine 113.75 USD  -13.64%

Kõrge 129 USD

Madal 100 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Novartis AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

1

Osta

3

Hoia

1

Müü

Tehniline skoor

By Trading Central

N/A / 112.63Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
help-icon Live chat